An oxygen therapeutic composition, which includes a perfluorocarbon material having a boiling point of about 4 degrees Celsius to about 60 degrees Celsius, a lipid; a viscosity modifier; a buffer.

An oxygen therapeutic composition, which includes a perfluorocarbon material having a boiling point of about 4 degrees Celsius to about 60 degrees Celsius, a lipid; a viscosity modifier; a buffer.

Compounds of formula (I): ##STR00001##
wherein R1 and R2 represent hydrogen or deuterium atoms; R3 represents a hydrogen atom or a COOH, a OH or a OPO(OH).sub.2 group; R4 represents a hydrogen atom or a fluorine atom; R5 represents a hydrogen atom or a OH group; wherein at least one of R3 or R5 is different from a hydrogen atom; when R3 represents a COOH, OH or OPO(OH).sub.2 group, then R5 represents a hydrogen atom; when R5 represents a OH group, then R3 and R4 represent hydrogen atoms; and R6 is selected from an optionally substituted phenyl, heteroaryl, cycloalkyl and heterocycloalkyl group;
and the preparation and the therapeutic uses of the compounds of formula (I) as inhibitors and degraders of estrogen receptors, useful especially in the treatment of cancer.

The present disclosure relates to compounds having the Formula (Formula (I)) which are inhibitors of STAT5. ##STR00001##

The present invention relates to fluorinated and alkylated bile acids.

The present invention relates to fluorinated and alkylated bile acids.

A system and method includes delivery of a redox gas solution to treat onychomycosis, wherein the redox gas solution comprises a reactive species dissolved in a perfluorocarbon liquid, and wherein the perfluorocarbon liquid is dispensed onto a gas-permeable membrane and the perfluorocarbon liquid comprises of an anti-inflammatory in a perfluorocarbon liquid and wherein the reactive species may include, alone or in combination, one or more of reactive oxygen, reactive nitrogen, reactive chlorine, or reactive bromine species, and the perfluorocarbon liquid may include perfluorodecalin.

The present invention provides a pharmaceutical composition comprising: a) a therapeutically effective amount of at least one cannabinoid receptor binding ligand, and b) a liquid vehicle comprising at least one semifluorinated alkane; as well as the use of such pharmaceutical compositions as a medicament.

The present invention provides a pharmaceutical composition comprising: a) a therapeutically effective amount of at least one cannabinoid receptor binding ligand, and b) a liquid vehicle comprising at least one semifluorinated alkane; as well as the use of such pharmaceutical compositions as a medicament.

The present invention provides means to affect the dynamics of actomyosin network in natural killer (NK) cells, and thereby to confer selective control on killing efficiencies of NK cell populations. Compositions and methods of the present invention, particularly those using small molecules, provide a powerful tool for controlling NK cell activation and function in various conditions, in health and disease, most notably in viral infections, autoimmunity, immunodeficiency, GVHD and cancer.